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Abstract: Inactivated poliovirus vaccine (IPV) may be
used in mass vaccination campaigns during the final
stages of polio eradication. It is also likely to be adopted
by many countries following the coordinated global
cessation of vaccination with oral poliovirus vaccine
(OPV) after eradication. The success of IPV in the control
of poliomyelitis outbreaks will depend on the degree of
nasopharyngeal and intestinal mucosal immunity induced
against poliovirus infection. We performed a systematic
review of studies published through May 2011 that
recorded the prevalence of poliovirus shedding in stool
samples or nasopharyngeal secretions collected 5–30 days
after a ‘‘challenge’’ dose of OPV. Studies were combined
in a meta-analysis of the odds of shedding among
children vaccinated according to IPV, OPV, and combina-
tion schedules. We identified 31 studies of shedding in
stool and four in nasopharyngeal samples that met the
inclusion criteria. Individuals vaccinated with OPV were
protected against infection and shedding of poliovirus in
stool samples collected after challenge compared with
unvaccinated individuals (summary odds ratio [OR] for
shedding 0.13 (95% confidence interval [CI] 0.08–0.24)). In
contrast, IPV provided no protection against shedding
compared with unvaccinated individuals (summary OR
0.81 [95% CI 0.59–1.11]) or when given in addition to OPV,
compared with individuals given OPV alone (summary OR
1.14 [95% CI 0.82–1.58]). There were insufficient studies of
nasopharyngeal shedding to draw a conclusion. IPV does
not induce sufficient intestinal mucosal immunity to
reduce the prevalence of fecal poliovirus shedding after
challenge, although there was some evidence that it can
reduce the quantity of virus shed. The impact of IPV on
poliovirus transmission in countries where fecal-oral
spread is common is unknown but is likely to be limited
compared with OPV.
Introduction
The development and licensing of inactivated poliovirus vaccine
(IPV) in 1955 and subsequently of the live-attenuated oral
poliovirus vaccine (OPV) in 1961 had an enormous impact on
poliomyelitis in the Western world and raised the possibility of
global eradication [1]. In 1988 the World Health Assembly
adopted a resolution to eradicate poliomyelitis, which led to a
successful global programme that has reduced the number of
children paralysed by poliomyelitis from approximately 350,000
each year to 1,349 in 2010. Eradication of poliomyelitis though the
use of these vaccines relies on herd immunity, whereby
unimmunized children are less likely to become infected because
neighboring children have been vaccinated. Eradication is
achieved even if all children have not been successfully immunized
so long as the average number of secondary infections generated
by each infected individual (the ‘‘reproduction number’’) is less
than 1.
Critically important to the herd immunity effect is the degree of
mucosal immunity offered by vaccination against infection and
shedding of poliovirus. The success to date of the Global Polio
Eradication Initiative (GPEI) in eliminating wild-type poliovirus
transmission from most of the world can largely be ascribed to
mass vaccination campaigns with OPV. This vaccine was chosen
not only because of the ease of administration, but also because of
its superior ability to induce local intestinal mucosal immunity [2].
Immunization with live-attenuated vaccine mimics natural
infection and results in the induction of a local secretory antibody
(IgA) response that is associated with a reduction in shedding of
poliovirus from the intestine [3,4]. In contrast, intramuscular
injection of IPV induces serum antibodies but does not induce
secretory IgA at the mucosal surfaces [3] and has a much more
limited impact on the resistance of the intestine to infection [5].
However, IPV can induce gut-homing lymphocytes and an
increase in the secretion of poliovirus-specific IgA among
individuals who have been previously exposed to live-attenuated
or wild-type poliovirus [6,7]. The impact of this immune boosting
on resistance of the intestine to infection is unknown.
After the eradication of wild-type polioviruses, coordinated
global cessation of the use of OPV is envisaged to prevent vaccine-
associated paralytic poliomyelitis and the emergence of vaccine-
derived polioviruses [8]. The majority of higher-income and some
middle-income countries that previously used OPV and have been
free of indigenous wild-type poliovirus transmission for several
years have already switched to IPV in their routine immunization
schedules for these same reasons. At the time of OPV cessation,
many other countries are likely to want to use IPV for a period of
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vaccine-derived or wild-type poliovirus. For this reason the GPEI
has supported an aggressive programme of research towards
developing an ‘‘affordable’’ IPV. This has included dose-reduction
strategies based on the addition of adjuvants, intradermal
administration, or reduced schedules; development of safer
poliovirus ‘‘seed’’ strains to allow manufacture of IPV in lower-
income countries; and engagement with vaccine manufacturers to
determine market size and supply capacity [9–11]. There have
also been calls for IPV use in areas with persistent wild-type
poliovirus transmission where OPV immunogenicity and effec-
tiveness are compromised [12]. In these settings a dose of IPV
could, it is argued, boost intestinal IgA better than an additional
dose of OPV.
The increasingly significant role of IPV highlights the need for a
better understanding of the impact of this vaccine, alone and in
combination with OPV, on nasopharyngeal and intestinal mucosal
immunity. Studies will be especially important in settings with
efficient fecal-oral transmission of poliovirus where herd-protec-
tion through the use of IPV has never been adequately
demonstrated [13].
Mucosal immunity to poliovirus in an individual can be assessed
by measuring vaccine poliovirus shedding after administration of a
‘‘challenge’’ dose of OPV. This is considered a reasonable
surrogate for immunity to infection with wild-type polioviruses
after natural exposure, although the relationship between
protection of the individual and prevention of transmission in
the population is not well defined.
A large number of poliovirus challenge studies of variable size,
location, and design have been published over the last 50 years.
Although a number of clinical trials that examine the impact of
IPV on mucosal immunity in tropical settings are currently under
way, review of published studies from a variety of settings will also
be fundamental in providing the evidence base on which countries
can make their decisions about the optimal vaccination strategy—
in the final stages of eradication and after global cessation of OPV
use. A number of review articles have examined some of the larger
OPV challenge studies [2,14,15], but we are not aware of any
attempt at a systematic review of the large and heterogeneous
group of published studies.
Here we present a systematic review of challenge studies that
examine poliovirus shedding in secretions in the nasopharynx and
in stool samples collected from individuals 5–30 days after
administration of OPV. We present a meta-analysis of the odds
of shedding poliovirus among studies that compared two or more
vaccination schedules using IPV, OPV, or a combination of these
vaccines. The implications for poliovirus vaccination policy are
discussed.
Results
Identified Studies
A total of 1,981 published articles were identified in the
PubMed and Web of Knowledge databases using the search terms
described in the Methods, and a further six studies were identified
from literature cited in key references (Figure 1). Screening the title
and abstracts of these articles resulted in 171 potentially relevant
papers, which were read in full-text to identify 31 studies of
poliovirus shedding in stool and four of shedding in the
nasopharynx that met the inclusion criteria for the analysis
(Tables S1 and S2). One publication included studies from three
different countries, and these are included in the systematic review
as separate studies [16].
Statistical Analysis
From the 31 studies of poliovirus shedding in stool, there were
22 studies that compared shedding after challenge with the same
OPV among individuals with different vaccination histories (Table
S1). Classification of these vaccination histories into unvaccinated,
OPV-only, IPV-only, and combined schedules permitted compar-
ison of OPV vaccinated with unvaccinated children (Figure 2),
IPV vaccinated with unvaccinated children (Figure 3), OPV with
IPV vaccinated children (Figure 4), and OPV vaccinated with
combined OPV/IPV vaccinated children (Figure 5; combined
schedules mainly involved simultaneous administration of IPV and
OPV, see figure legend for details). Summary odds ratios (ORs) for
these comparisons were calculated independently for each
poliovirus serotype based on fixed (n=7) or random (n=4) effect
models according to the significance of the x
2 test for
heterogeneity. Only one study compared serotype 2 poliovirus
shedding in OPV-only and OPV/IPV vaccinated individuals, and
so a summary OR was not calculated (Figure 5). There was no
evidence for an association between individual study ORs and
study size. In total, results from 18 studies were included in the
meta-analyses that compared different vaccination histories.
Only four studies that met the inclusion criteria for the
systematic review examined poliovirus shedding in the nasophar-
ynx after administration of OPV (Table S2). Two of these studies
compared IPV vaccinated with OPV vaccinated children and one
compared IPV vaccinated with unvaccinated children. Very few
samples were positive for poliovirus in these studies, and there was
insufficient power to compare the prevalence of poliovirus in the
nasopharynx of children with different vaccination histories.
Discussion
Systematic review and meta-analysis of published studies
confirms the large protective effect of prior immunization with
OPV on shedding of poliovirus in the intestine following
administration of a challenge dose of OPV. The odds of vaccine
poliovirus shedding was significantly reduced among children
immunized solely with OPV compared with unvaccinated
children (overall OR 0.13 [95% CI 0.08–0.24]). In contrast, IPV
had no significant impact on the prevalence of challenge poliovirus
shedding in stool samples, either on its own or when added to an
OPV schedule (overall ORs 0.81 [0.59–1.11] and 1.14 [0.82–
1.58], respectively). The superior impact of OPV on intestinal
mucosal immunity is confirmed by the meta-analysis of studies that
directly compared schedules that exclusively used OPV or IPV
(overall OR for OPV compared with IPV immunized children was
0.15 [0.08–0.27]).
Although IPV does not significantly reduce the prevalence of
poliovirus shedding in stool samples collected after challenge, it
may reduce the duration and quantity of virus shed compared
with unvaccinated children. Five studies that quantified poliovirus
shedding found a 63%–91% (or an absolute 0.43–1.0 log10)
reduction in the mean quantity of poliovirus shed in stool samples
collected from IPV vaccinated compared with unvaccinated
children [5,17–20] (Table S1). Three of these studies also
examined the duration of shedding and two found a shorter
period of shedding in IPV vaccinated children [17,19]. Using
data from one of these studies [17], it has been noted that the
combined reduction in both the quantity and duration of vaccine
poliovirus shedding would reduce the total amount of poliovirus
shed during the course of an infection by approximately 95%
[15]. Because IPV is unable to induce a secretory IgA response in
the intestine of naı ¨ve individuals, it has been suggested that
secondary exposure to OPV shed by vaccinated children or to
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mucosal immune response of children in some of these earlier
studies. The effect of IPV could therefore be at least partially
explained by boosting of secretory IgA among mucosally primed
individuals [7]. However, the low prevalence of non-challenge
poliovirus serotypes in stool samples collected during these studies
suggests that mucosal priming was limited, and in the more
recent study the possibility of secondary exposure to poliovirus
was deliberately excluded [18]. The impact of IPV in these
studies is perhaps more likely to relate to local immunity induced
by IPV through transudation of serum IgG rather than induction
of a local secretory IgA response [7].
There were insufficient studies that examined the impact of IPV
or OPV on poliovirus shedding in the nasopharynx after
administration of OPV to draw any conclusions. Three studies
of wild-type poliovirus shedding in the nasopharynx after natural
exposure during epidemics in the United States in 1956–1960
found a lower prevalence of shedding among children who had a
history of vaccination with IPV [21–24]. This reduction in
shedding was not apparent when stool samples were examined.
However, interpretation of these studies is limited by their small
size and the potential for confounding by age and socioeconomic
status between IPV immunization status and the degree of
exposure to wild-type poliovirus.
Figure 1. Flow diagram showing included studies according to PRISMA guidelines [46]. The number of published articles identified by the
given search term for initial screening and the resulting studies identified and included in the systematic review and meta-analysis are shown.
doi:10.1371/journal.ppat.1002599.g001
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vaccinated children observed in challenge studies and the impact
of vaccination on wild-type or vaccine-derived poliovirus
circulation is unknown and likely to vary significantly according
to the characteristics of the population. Challenge with a high
titer of attenuated vaccine (Sabin) poliovirus, which is homolo-
gous to the immunizing strain in the case of OPV vaccinees, is
different than natural exposure to wild-type poliovirus, which has
an estimated median infectious dose for humans of about 10
median tissue culture infectious doses (TCID50) compared with
about 10
3 for Sabin polioviruses [25]. Furthermore, the
relationship between the quantity of virus shed and the
probability of onwards transmission is unknown and likely to
depend on the importance of different routes of transmission and
dissemination in the environment.
The impact of IPV on poliovirus circulation is expected to be
more limited compared with OPV in areas with poor sanitation
and efficient fecal-oral transmission because of the absence of any
significant effect of this vaccine on the prevalence of poliovirus
shedding in stool. However, there are no studies with adequate
control populations that investigate the impact of IPV on wild-type
poliovirus transmission in such areas [13]. Indeed, IPV has rarely
been used in lower-income countries except as part of private
practice. The recent switch to routine immunization with IPV in a
pilot project in Yogyakarta in Indonesia and in a number of
middle-income countries in South America may provide some
information about the ability of IPV to prevent circulation of
vaccine-derived polioviruses in areas with poor sanitation, given
the continued use of OPV in neighboring areas or during national
immunization days, respectively [26,27].
Figure 2. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with
unvaccinated individuals. Odds ratios (ORs) and 95% confidence intervals for individual studies are indicated by the boxes and grey lines. The
summary odds ratio for each serotype is given by a diamond with the 95% confidence interval (CI) indicated by its width. The x
2 test for
heterogeneity among studies was significant for serotypes 2 and 3 (p-values 0.33, ,0.001, and 0.001 for serotypes 1, 2, and 3, respectively) and for the
overall odds ratio (p-value,0.001). Details of the studies included are given in Table S1. *Ghendon et al. 1961 [17] compare vaccinated and
unvaccinated children who were confirmed seropositive and seronegative, respectively.
doi:10.1371/journal.ppat.1002599.g002
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Finland, Iceland), IPV schedules have resulted in the eradication
of wild-type polioviruses and protected against large outbreaks of
paralytic disease for several decades [28]. The impact of IPV in
these countries has been attributed to an effect of IPV on shedding
in the nasopharynx in settings where oral-oral transmission is likely
to predominate. Where importations of wild-type polioviruses to
these countries have been documented, they have resulted in
outbreaks ranging from a single case to over 100 cases of
poliomyelitis [29–32]. These outbreaks have usually been
restricted to unvaccinated communities, indicating the reduction
in poliovirus transmission that results from vaccination with IPV.
To date, no outbreaks have been reported from countries that
have recently switched to exclusive use of IPV. However, there is
some evidence from Israel that IPV-using communities are more
at risk compared with OPV-using communities [33]. Furthermore,
asymptomatic wild poliovirus shedding has been detected among
IPV vaccinated children during outbreaks in these European
countries, albeit at lower frequencies than in unvaccinated
children [32,34]. IPV vaccinated children may therefore play a
role in the circulation of imported wild poliovirus, and for this
reason these outbreaks have usually been controlled through the
reintroduction of OPV to induce adequate mucosal immunity to
stop transmission.
In some of the comparisons of vaccination schedules, the meta-
analysis identified significant heterogeneity in the OR from
different studies. Heterogeneity is likely to arise from a number
of sources, including variable times for sample collection after
challenge, different numbers and timing of vaccine doses prior to
challenge, and variable laboratory procedures, as well as
unmeasured factors such as the prevalence of enteric infections
that may interfere with vaccine poliovirus shedding. Indeed, the
prevalence of challenge poliovirus shedding was highly variable
among studies, even for those that examined very similar
vaccination schedules (Table S1). There were insufficient studies
to permit a formal meta-regression model that included these
variables. However, we did examine some of them by stratifying
the meta-analysis and present the results together with the number
of doses of vaccine received prior to challenge because of the
association of this variable with the prevalence of shedding
(Figures 2–5). For example, studies that compared poliovirus
shedding among children who had received just a single dose of
OPV with unvaccinated children typically found a limited impact
on serotype 3 poliovirus, presumably because of the poor
immunogenicity of a single dose of serotype 3 Sabin poliovirus,
particularly in the trivalent formulation [35].
Despite over 50 years of vaccination with Salk’s IPV, questions
remain about the ability of this vaccine to prevent poliovirus
circulation in remaining polio-endemic countries. In addition,
basic immunology research is required to better understand the
mucosal immune response to both IPV and OPV, and in
particular the adaptive cellular and innate components [36,37].
Figure 3. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV compared with
unvaccinated individuals. Labeling as for Figure 2. The x
2 test for heterogeneity among studies was not significant for any serotype (p-values 0.11,
0.47, and 0.07) or for the overall odds ratio (p-value 0.10). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were
confirmed seropositive and seronegative, respectively.
doi:10.1371/journal.ppat.1002599.g003
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poliovirus within a year of vaccination with OPV [38] and
identification of wild-type polioviruses in stool samples from OPV
immunized children [39] has generated interest in the potential for
IPV to boost intestinal immunity among these children. Studies of
immune boosting following IPV or OPV are therefore currently
under way to assess the possible role for IPV in combination with
OPV to interrupt wild-type poliovirus transmission in endemic
countries. After eradication of wild-type polioviruses and global
cessation of vaccination with OPV, the role of IPV in lower-income
countries has yet to be defined. Research towards an affordable IPV
aims to provide the option to use this vaccine during routine
immunization and could protect children from poliomyelitis in the
event of an outbreak of wild-type or vaccine-derived poliovirus. It is
unknown whether this vaccine would limit the spread of poliovirus,
but it would potentially provide the protection needed before an
outbreak response using OPV. Continued research and program-
matic use of IPV will eventually provide evidence for the impact of
IPV on poliovirus circulation in countries with fecal-oral transmis-
sion of infection. It is hoped that this evidence will emerge in the
context of successful global eradication of poliomyelitis.
Materials and Methods
Identification and Review of Studies
A literature search was carried out in May 2011 using the
PubMed (http://www.ncbi.nlm.nih.gov) and ISI Web of Knowl-
edge (http://isiknowledge.com) citation databases by searching
title, abstract, and keywords with the search term ‘‘polio* and
(shed* or excret* or stool or faece* or fece* or throat or naso*)’’.
The asterisk functions as a wildcard that permits partial word
matching. We did not apply any language or publication
restrictions except the restrictions of the databases themselves.
Additionally, the bibliographies of key studies and reviews were
examined to identify further relevant studies [2,14,40]. Publica-
tions in languages other than English that did not provide an
English summary were translated by the authors or proficient
speakers.
The titles and abstracts of articles identified by the initial search
were screened and those that did not describe measures of
poliovirus-specific immunity or shedding of vaccine poliovirus
were removed. Full-text copies of the remaining articles were read
using documents sourced from the original electronic journals or
the holdings of the British Library. Data on the prevalence and
quantity of vaccine poliovirus shed in nasopharyngeal or stool
samples were extracted from those articles that met the inclusion
criteria. These were: 1) study records the prevalence of vaccine
poliovirus shedding in stool or nasopharyngeal samples collected
after administration of a challenge dose of live-attenuated
poliovirus; 2) samples collected 5–30 days after challenge
(shedding of virus up to 4 days after challenge was excluded,
because it has been suggested that this can be the result of transient
passage of vaccine rather than infection of the mucosal surfaces
[41]). Studies were excluded if they: 1) duplicated findings
Figure 4. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with IPV.
Labeling as for Figure 2. The x
2 test for heterogeneity among studies was significant for serotypes 1 and 3 (p-values,0.001, 0.79, and 0.01 for
serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value,0.001). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated
children who were confirmed seropositive and seronegative, respectively.
doi:10.1371/journal.ppat.1002599.g004
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included fewer than 30 individuals; 4) included insufficient
information describing poliovirus serotype, vaccine schedules
prior to challenge, or prevalence of shedding by individual rather
than by sample; 5) challenged with OPV more than 5 years after
vaccination. These criteria ensured consistent information was
available for all studies, minimizing the risk of selective reporting
of favorable results within a study.
Data that were extracted from studies meeting the inclusion
criteria were the vaccine type and schedule prior to challenge,
challenge vaccine type and dose, the nature of the sample, and the
laboratory methods (cell culture–based versus direct detection
using real-time PCR). The number of individuals who shed or did
not shed vaccine poliovirus was recorded by serotype and time of
sample collection. Where samples were collected at multiple time
points, these data were recorded separately. Data on the quantity
of vaccine poliovirus shed based on titration of samples or
quantitative PCR were recorded where available. We also
recorded the mean duration of shedding when given or estimated
this from the data where possible by taking the mean of an
exponential curve fit to the prevalence of shedding over time using
a least-squares approach. Data were extracted independently by
the two authors and compared for errors before producing a
consolidated database. Where reported data were incomplete, an
effort was made to contact the authors of the relevant studies.
Statistical Analysis
We included challenge studies that compared shedding of
challenge poliovirus across two or more vaccination schedules in a
meta-analysis. Where stool samples were available for more than
one time point, we used data from the sample taken closest to 7
days after challenge. For the purposes of the meta-analysis,
schedules were grouped into four categories—unvaccinated,
trivalent OPV only, IPV only, and combined schedules—and
the relative odds of poliovirus shedding calculated in pairwise
comparisons between these groups. There were insufficient studies
of monovalent or bivalent OPV immunization schedules to
warrant a separate category for these vaccines. We only compared
combined schedules with OPV or IPV-only schedules where the
combination schedule involved the administration of additional
doses of IPV (we did not, for example, include studies that
compared a schedule of six doses of trivalent OPV with a schedule
of five doses of trivalent OPV and one dose of IPV, as examined in
some studies, e.g., [42]). Evidence for heterogeneity among studies
was assessed on the basis of the x
2 statistic [43]. Summary ORs
and 95% confidence intervals were calculated on a log scale
assuming either fixed effects or normally distributed random
effects among studies according to the results of the x
2 test [44].
The association between the individual study ORs and study size
was examined for evidence of potential publication bias. All
analyses were implemented in the R programming language using
the rmeta package [45].
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Table S1 Studies included in the systematic review that
examined poliovirus shedding in stool samples taken
after administration of OPV. Vaccination schedules are given
Figure 5. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV in addition to OPV
compared with individuals vaccinated with OPV only. Labeling as for Figure 2. The schedule indicates the number and type of OPV doses
received by both groups and the number of doses of IPV that were added in the intervention group. In two studies, IPV was administered
simultaneously with OPV at 6, 10, and 14 weeks (Modlin et al. 1997 [47] and du Chatelet et al. 2003 [48]), and in one study IPV was administered
before and at the same time as OPV (schedule was IPV, IPV/OPV, OPV, OPV at 2, 4, 6, 15 months; WHO Collaborative Study Group on Oral and
Inactivated Poliovirus Vaccines 1997 [49]). The x
2 test for heterogeneity among studies for serotypes 1 and 3 was not significant for each serotype (p-
values 0.13 and 0.08) or for the serotypes combined (p-value 0.14).
doi:10.1371/journal.ppat.1002599.g005
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tOPV=trivalent OPV, mOPV1=serotype 1 monovalent OPV,
mOPV3=serotype 3 monovalent OPV, bOPV2,3=bivalent
OPV containing serotypes 2 and 3. -=not available. Mean
duration of shedding was estimated from the fit of an exponential
curve to the prevalence of shedding over time unless given directly
in the paper.
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Table S2 Studies included in the systematic review that
examined poliovirus shedding in nasopharyngeal secre-
tions after administration of OPV. Vaccination schedules
are given as the number of doses followed by the type of vaccine.
tOPV=trivalent OPV, mOPV1=serotype 1 monovalent OPV.
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